Use Cases.
10 articles on use cases — analysis from the Asthra team and our advisor network.
2026
Atara, Pierre Fabre, and the Third-Shot Submission: Anatomy of a Post-Rejection Rewrite
FDA has indicated a path to reconsider Atara and Pierre Fabre's twice-rejected tabelecleucel BLA. In a third-shot package, the writing function becomes load-bearing: every claim, analysis, and cross-reference has to map back to the prior CRL.
2026
From IPO to First Annual Report: The Disclosure Stack Newly Public Biotechs Miss
An IPO doubles a biotech's disclosure workload overnight. The regulatory writing function rarely gets re-resourced in time. Here is what gets missed and how to plan against it.
2026
Milestone Payments as a Writing-Pace Forcing Function
When a partnership milestone pays, the regulatory writing function inherits a calendar. The partnership announcement is the loud event. The document acceleration that follows is the quiet one.
2026
The $5B Impairment and the Documentation Lifecycle
When a commercial decision retroactively reshapes a product's value, the documentation stack does not auto-adjust. The CSL impairment this week is a case study in why regulatory writing needs to be in the room before the writedown.
2026
Daiichi Sankyo's $950M ADC Write-Down: Decommissioning the Capex Bet
Daiichi recorded a ¥149.4B 'extraordinary loss' on May 8 after scrapping antibody-drug-conjugate manufacturing capacity. The decommissioning problem returns — this time at the capex level, with documentation implications that follow.
2026
Decommissioning a Program's Documentation Stack: When the Sponsor Terminates
Pfizer ending its Trillium-related programs is the headline. The regulatory writing question is what happens to the documentation, the audit trail, and the institutional memory when a sponsor closes a program down — especially mid-stream.
2026
Orphan Drug Designation and the Six-Month CSR Calendar Reset
Orphan Drug Designation is celebrated as good news. For the regulatory writing function, it is a calendar event that compresses CSR, briefing book, and pre-BLA preparation into a much tighter window than most teams plan for.
2026
Phase 2 Win + Capital Raise = Six Months of Documentation Crunch
A positive Phase 2 readout followed by a financing round looks like a celebration. For the regulatory writing function, it's the start of a 180-day timeline collision that most teams underestimate.
2026
Project Optimus and the ORR Bridge: When Confirmatory Readouts Have to Carry More Than the Primary
Post-Project Optimus, the FDA's tolerance for narrow ORR-based accelerated approvals has tightened. The CSR and BLA narrative for a confirmatory readout now has to do framing work the primary readout used to do alone.
2025
CSR Timelines: From One Month to Less Than 10 Days
How AI-assisted drafting is compressing Clinical Study Report timelines from weeks of manual effort to days of focused writing, without compromising quality or traceability.
See it on a real CSR, PSUR, or CER.
Asthra's five-step loop — Plan, Retrieve, Draft, Review & refine, Hand off — running on real regulatory documents, not slides.